Table 1. Phosphoglucomutase (PGM 1) Deficiency Diagnostic Guidelines

Table 2. Treatment Guidelines

Table 3. Assessment Summary

Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis

Table 5. Phosphoglucomutase (PGM 1) Deficiency Acquisition Analysis

Table 6. Assessment by Phase of Development

Table 7. Assessment by Product Type (Mono / Combination)

Table 8. Assessment by Stage and Product Type

Table 9. Assessment by Route of Administration

Table 10. Assessment by Stage and Route of Administration

Table 11. Assessment by Molecule Type

Table 12. Assessment by Stage and Molecule Type

Table 13. Assessment by MOA

Table 14. Assessment by Stage and MOA

Table 15. Late Stage Products (Phase-III)

Table 16. Mid Stage Products (Phase-II)

Table 17. Early Stage Products (Phase-I)

Table 18. Pre-clinical and Discovery Stage Products

Table 19. Inactive Products

Table 20. Dormant Products

Table 21. Discontinued Products

"Phosphoglucomutase (PGM 1) Deficiency- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Phosphoglucomutase (PGM 1) Deficiencypipeline landscape is provided which includes the disease overview and Phosphoglucomutase (PGM 1) Deficiencytreatment guidelines. The assessment part of the report embraces, in depth Phosphoglucomutase (PGM 1) Deficiencycommercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Phosphoglucomutase (PGM 1) Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Phosphoglucomutase (PGM 1) DeficiencyUnderstanding
Congenital disorders of glycosylation (CDGs) are a group of genetic metabolic diseases that are caused by defects in protein glycosylation. Phosphoglucomutase-1 deficiency (PGM1-CDG) is a special CDG that offers new insights into the highly complex relationship among protein glycosylation, other metabolic pathways, and organ system development, according to Sunnie Yan et al (2016). PGM1 Deficiency is caused by loss of function mutations in the PGM1 gene encoding an enzyme responsible for the interconversion of glucose-6-phosphate to glucose-1-phosphate. Glucose-1-phosphate can be utilized to supply UDP-galactose, a substrate that donates galactose subunits for glycoprotein synthesis. The phenotype of PGM1-CDG comprises a wide range of clinical manifestations, including hypoglycemia, congenital malformations, early-onset dilated cardiomyopathy, growth retardation, hormonal deficiencies, hepatopathy, hemostatic anomalies, and myopathy.
Phosphoglucomutase (PGM 1) DeficiencyPipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Phosphoglucomutase (PGM 1) Deficiencytargeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Phosphoglucomutase (PGM 1) Deficiencypipeline report covers only one company. Some of the key players include Cerecor Inc. (CERC-801) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Phosphoglucomutase (PGM 1) DeficiencyAnalytical Perspective by DelveInsight
• In-depth Phosphoglucomutase (PGM 1) Deficiency Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Phosphoglucomutase (PGM 1) Deficiency Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Phosphoglucomutase (PGM 1) Deficiencyreport provides an overview of therapeutic pipeline activity for Phosphoglucomutase (PGM 1) Deficiencyacross the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Phosphoglucomutase (PGM 1) Deficiencytherapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Phosphoglucomutase (PGM 1) DeficiencyResearch and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Phosphoglucomutase (PGM 1) Deficiency
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Phosphoglucomutase (PGM 1) Deficiencyto formulate effective R&D strategies
• Assess challenges and opportunities that influence Phosphoglucomutase (PGM 1) DeficiencyR&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Phosphoglucomutase (PGM 1) Deficiencyin licensing and out licensing strategies by identifying prospective partners with progressing projects for Phosphoglucomutase (PGM 1) Deficiencyto enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs